Indolent B-cell Lymphoma Recruiting Phase 2 Trials for Ledipasvir (DB09027)

IndicationStatusPhase
DBCOND0043724 (Indolent B-cell Lymphoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02836925Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionTreatment